Arsenol (arsenic trioxide oral) / SDK Therapeutics - LARVOL DELTA

Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic Leukemia (clinicaltrials.gov) - P1/2 | N=12 | Recruiting | Sponsor: SDK Therapeutics, Inc.

New P1/2 trial • Acute Promyelocytic Leukemia • Hematological Malignancies • Leukemia • Oncology

Arsenolipid-Induced Reproductive Toxicity in Caenorhabditis elegans: Elucidating the Mechanism through the HUS-1-CEP-1-EGL-1-CED-9-CED-4-CED-3 Signaling Pathway. (PubMed, Food Chem Toxicol) - "In addition, the mechanism of arsenolipid-induced nematode reproductive toxicity was further elucidated through the HUS-1-CEP-1-EGL-1-CED-9-CED-4-CED-3 signaling pathway. Therefore, our results suggest that AsHC 332 is more exposed to reproductive toxicity than AsHC 346 and AsHC 360, which is related to changes in physicochemical properties and DNA damage-induced germ cell apoptosis."

Journal • APAF1 • GAS1 • SOD3

Orphan Designation: treatment of acute promyelocytic leukemia (FDA) - Date Designated: 11/19/2024

Orphan drug • Acute Promyelocytic Leukemia